All publications

Export 167 results:
Author Title Type [ Year(Asc)]
2012
Sethi G, Sabin CA, Lycett S, Ragonnet-Cronin M, Edwards SG, Fearnhill E, Dunn DT, Delpech V, Phillips AN, Pillay D et al..  2012.  Phylogenetic analysis of HIV transmission among different ethnic MSM groups in the UK. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Hodcroft E, Fearnhill E, Phillips AN, Dunn DT, Pillay D, Hadfield J, Leigh Brown A, UK HIV Drug Resistance Database.  2012.  Population based study indicates viral genetic effect on HIV virulence is small but significant. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012.
Donegan K.L, Walker A.S, Dunn DT, Judd A, Pillay D, Menson E, Lyall H., Tudor-Williams G, Gibb DM.  2012.  The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.
Koning FA, Castro H, Dunn DT, Mbisa JL, Cane P A, UK HIV Drug Resistance Database.  2012.  Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.
Dolling D, Sabin CA, Delpech V, Smit E, Pozniak A, Asboe D, Leigh Brown A, Churchill D, Williams I, Geretti AM et al..  2012.  Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.
Foster GM, Ambrose JC, Hue S, Delpech V, Fearnhill E, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2012.  Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.
2011
Cozzi-Lepri A, Prosperi M.C, Kjaer J., Dunn DT, Paredes R, Sabin CA, Lundgren J, Phillips AN, Pillay D.  2011.  Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.
Ambrose JC, Foster GM, Fearnhill E, Leigh Brown A, Porter K, Mackie N, Fidler S, Geretti AM, On behalf of the UK Register of HIV Seroconverters and the UK HIV Drug Resistance Database.  2011.  The contribution of recent infections to HIV-1 transmission clusters in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.
Prosperi M.C, Mackie N, Di Giambenedetto S., Zazzi M, Camacho R., Fanti I., Torti C., Sonnerborg A., Kaiser R., Codoner F.M et al..  2011.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.
Santoro MM, Silberstein FC, Forbici F., Bansi L, Dunn DT, Fearnhill E, Boumis E, Narciso P, Antinori AM, Palamara G et al..  2011.  Different drug-resistance development in HIV-1 infected patients failing a first-line antiretroviral therapy containing NNRTIs. IAS, 17-20 July 2011.
Wittkop L., Günthard HF, de Wolf F., Dunn DT, Cozzi-Lepri A, De Luca A., Kucherer C., Obel N., von Wyl V., Masquelier B. et al..  2011.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.
Dunn DT, Coughlin K., Cane P A.  2011.  Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT, UK Collaborative Group on HIV Drug Resistance.  2011.  HIV transmission dynamics. Keystone Conference on HIV Evolution, Genomics and Pathogenesis, 26-31March 2011.
Bansi L, Smith C, Phillips AN, Kirk S., Geretti AM, Johnson M, Mackie N, Post FA, Gazzard B, Dunn DT et al..  2011.  The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.
Klein M, Odueyungbo A, Scherrer A, Ledergerber B, Fearnhill E, Sabin CA, Hogg R, Cozzi-Lepri A, Gill J, Tan D et al..  2011.  Impact of Viral Subtype on Immunologic and Clinical Disease Progression in Antiretroviral-naïve HIV-infected Adults. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Foster GM, Ambrose JC, Hue S, Conibear T, Fearnhill E, Abecasis AB, Leigh Brown A, Geretti AM, UK HIV Drug Resistance Database.  2011.  Mapping the circulation of HIV-1 recombinants among MSM. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Hue S, Fearnhill E, Dunn DT, Delpech V, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2011.  Phylogeographic and Risk Group Characteristics of HIV Subtype A Transmission in the UK. 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Hue S, Fearnhill E, Dunn DT, Delpech V, Pillay D, Leigh Brown A, UK HIV Drug Resistance Database.  2011.  Phylogeographic and risk group characteristics of HIV-1 Subtype A transmission in the UK. 18th International HIV Dynamics and Evolution Conference, 1-4 May 2011.
Mackie N, Garvey L, Geretti AM, Harrison LJ, Tilston P, Phillips AN, Sabin CA, Dunn DT.  2011.  Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Barber TJ, Harrison LJ, Asboe D, Williams I, Bansi L, Pillay D, Dunn DT.  2011.  Prevalence and predictors of protease inhibitor (PI) mutations in HIV-infected UK adults treated with ritonavir-boosted lopinavir as their first PI. 17th Annual Conference of the British HIV Association, 6-8 April 2011.